Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Top Cited Papers
- 18 February 2021
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (7), 673-674
- https://doi.org/10.1056/nejmc2030164
Abstract
CD19-directed chimeric antigen receptor (CAR)–modified T cells are now widely used to treat some relapsed or refractory aggressive B-cell lymphomas.1-5 However, data on outcomes beyond 2 years after CAR T-cell infusion are limited. We previously reported 28-month outcomes in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma who were treated with CD19-directed, 4-1BB costimulated CAR T cells (tisagenlecleucel [CTL019]).5 We now report the results of the 5-year outcomes of that trial.Keywords
This publication has 5 references indexed in Scilit:
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaThe New England Journal of Medicine, 2020
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaThe New England Journal of Medicine, 2019
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trialThe Lancet Oncology, 2018
- Chimeric Antigen Receptor T Cells in Refractory B-Cell LymphomasThe New England Journal of Medicine, 2017
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaThe New England Journal of Medicine, 2017